IBA Overhauls Board with Oncology, Regulatory Experts Amid Dividend Payout
Event summary
- IBA adds Joyce Hansen (sterilization science) and Stephen Hahn (oncology/regulatory) to its board, replacing Sybille van den Hove and Muriel de Lathouwer.
- Hahn previously led FDA and Harbinger Health, while Hansen retired from Johnson & Johnson after 40 years in microbiology.
- Board approved €0.25 per share dividend for 2025, payable July 1, 2026.
- Departing directors include sustainability leader Sybille van den Hove.
The big picture
IBA's board refresh signals a strategic pivot toward regulatory and oncology expertise as the company navigates tightening medical device standards and expanding into advanced cancer treatment technologies. The dividend payout reflects stable cash flows despite governance transition. The move comes as competitors accelerate AI-driven diagnostic innovations, pressuring traditional radiation therapy players to differentiate through regulatory agility and clinical outcomes.
What we're watching
- Regulatory Alignment
- How Stephen Hahn's FDA experience will shape IBA's approach to evolving medical device regulations.
- Sustainability Gap
- Whether IBA can maintain its B Corp status without Sybille van den Hove's leadership.
- Oncology Focus
- The pace at which IBA integrates Hahn's radiation oncology expertise into its proton therapy strategy.
Related topics